New! Dexlansoprazole 60 mg Delayed-Release Capsules
New! Dexlansoprazole 60 mg Delayed-Release Capsules Wexford Laboratories is proud to present its latest pharmaceutical innovation: Dexlansoprazole 60 mg delayed-release capsules, a proton pump inhibitor (PPI) widely recommended for the treatment of erosive esophagitis, as well as gastric and duodenal ulcers. Patient Benefits Our Dexlansoprazole offers multiple advantages for patients requiring effective treatment for gastroesophageal … Read more